1065 Beyond the Incision: Optimising Secondary Prevention Prescriptions for Vascular Surgery Admissions Through a Closed Loop Audit

T Ekkunagul,J Francis,W Ngwira,S Drever,C MacLeod,B Renwick

DOI: https://doi.org/10.1093/bjs/znae163.293

2024-07-01

Abstract:Abstract Aim Vascular surgery patients carry some of the highest chronic disease and mortality burden, often driven by atherosclerotic, pro-thrombotic pathophysiology. Cardiovascular mortality risk reduction through secondary prevention by anti-platelets and statins is essential, but studies repeatedly demonstrate deficiencies in initiating such therapies. We aim to improve the identification and initiation of secondary prevention agents for vascular surgery inpatients at a tertiary centre through education and structured handover practice. Method A retrospective audit was performed on pre-admission and on-discharge anti-platelet and statin prescribing in vascular surgery admissions from August-October 2023. Education on guidance-based secondary prevention therapies was delivered, and modifications to the daily handover pro-forma were implemented to monitor prescribing. A prospective post-intervention re-audit was subsequently performed on admissions from October-November 2023. Results On admission, 70% of the 89 pre-intervention and 49% of the 47 post-intervention cohorts presented with concurrent anti-platelet or anti-coagulant and statin therapy. Pre-intervention, anti-platelets were initiated by discharge in 36% of patients admitted without anti-platelets or anti-coagulants, and statins were initiated in 20% of patients admitted without lipid-lowering therapy. This increased to 55% and 41% of such patients respectively post-intervention. However, 15% and 13% of the pre- and post-intervention cohorts respectively remain discharged on no secondary prevention therapies. Conclusions Education and modifications to handover documentation improved the identification and prescribing of secondary prevention therapy for vascular surgery patients in relative terms. Patients without secondary prevention therapies accounted for a significant proportion of admissions irrespective of time-period and there remains further scope to improve secondary prevention prescribing in this high-risk patient group.